GlassScriptPhysician profile
Gregory T Stephens
NPI 1255306460
$4,068.51
in general payments reported to CMS, 2019-2025
34 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $484 · 2021: $1,214 · 2022: $1,210 · 2023: $720 · 2024: $332 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.68 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $859.98 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $664.45 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $546.31 | 2020-2024 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $295.02 | 2020-2023 | Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $193.21 | 2020-2022 | |
| Lilly USA, LLC | $189.42 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Amarin Pharma, INC. | $173.43 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.83 | 2020-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $146.85 | 2022 | |
| Abbott Laboratories | $82.13 | 2022-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $80.92 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $75.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.99 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $48.36 | 2022-2023 | Quviviq |
| Corium, LLC | $47.64 | 2022-2023 | Azstarys |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.72 | 2023-2025 | |
| Glaxosmithkline, LLC. | $38.13 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $34.76 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $33.76 | 2021-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $32.21 | 2021-2022 | |
| Phadia US INC. | $28.88 | 2025 | Immunocap |
| Daiichi Sankyo INC. | $23.29 | 2022 | |
| Impulse Dynamics (USA) INC. | $23.07 | 2023 | Optimizer |
| Esperion Therapeutics, INC. | $22.61 | 2021 | |
| Philips North America LLC | $21.81 | 2024 | (Ck6) Holter |
| Lundbeck LLC | $21.80 | 2023 | Vyepti |
| Actelion Pharmaceuticals US, INC. | $18.40 | 2023 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $17.67 | 2022 | |
| Gilead Sciences, INC. | $16.67 | 2021 | |
| Atricure, INC. | $16.17 | 2022 | |
| Medtronic, INC. | $16.14 | 2022 | |
| Insulet Corporation | $14.45 | 2021 | |
| Currax Pharmaceuticals LLC | $13.34 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.